Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207957 | 1.00 | KMT2A (0.40) | KMT2ALMNASMN1; SMN2HTR1A | |
| SCHEMBL31632741 | 0.77 | BRD4 (0.48) | — | |
| SCHEMBL8497766 | 0.76 | HTR2A (0.35) | KMT2ALMNASMN1; SMN2HTR1A | |
| SCHEMBL30433966 | 0.75 | — | — | |
| SCHEMBL17866942 | 0.74 | HTR1A (0.45) | HTR1A | |
| SCHEMBL10283677 | 0.74 | KMT2A (0.47) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6468219 | 0.74 | KMT2A (0.47) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6365121 | 0.74 | KMT2A (0.47) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL31404681 | 0.73 | HTR2C (0.40) | — | |
| SCHEMBL761306 | 0.72 | SMN1; SMN2 (0.49) | KMT2ALMNASMN1; SMN2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2025-12-04 | — | — | US | disclosed |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2025-11-18 | — | — | US | disclosed |
| WO-2025015254-A2 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE OF COMBINATION THERAPY FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | TRAN LLOYD (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240398792-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING, RELIEVING, OR ALLEVIATING ALZHEIMER'S DISEASE | BIOMED INDUSTRIES, INC. | 2024-12-05 | — | — | US | disclosed |
| US-12070458-B2 | Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders | BIOMED INDUSTRIES, INC. | 2024-08-27 | — | — | US | disclosed |
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2024-04-25 | — | — | US | disclosed |
| EP-4291192-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | Neuren Pharmaceuticals Limited (NZ) | 2023-12-20 | — | — | EP | disclosed |
| US-20230381175-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | BIOMED INDUSTRIES, INC. | 2023-11-30 | — | — | US | disclosed |
| CN-116916921-A | Treatment of Prader-Willi syndrome | 诺仁制药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2023-09-28 | — | — | US | disclosed |
| US-8067425-B2 | Neuroprotective bicyclic compounds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-11-29 | — | — | US | disclosed |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-03-03 | — | — | US | disclosed |
| US-7776876-B2 | Cyclic G-2Allylproline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS, LTD. (NZ) | 2010-08-17 | — | — | US | disclosed |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | BICKERDIKE MIKE JOHN | 2009-10-22 | — | — | US | disclosed |
| WO-2008063311-A2 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-08-23 | — | — | US | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| EP-1664050-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Neuren Pharmaceuticals Limited (NZ) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023815-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | KMT2A 500/4885LMNA 3336/4885SMN1; SMN2 3863/4885 |
| US-20110052531-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY | PMP22, IAPP, GCG | KMT2A 4137/4885LMNA 2555/4885SMN1; SMN2 170/4885 |
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | COMT, HSD17B3, HSD3B1 | KMT2A 901/4885LMNA 3881/4885SMN1; SMN2 484/4885 |
| US-20110201614-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | GRIA2, QPCT, GRM2 | KMT2A 2570/4885LMNA 3439/4885SMN1; SMN2 928/4885 |
| US-20230381175-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS | PYGB, GRN, BDNF | KMT2A 2003/4885LMNA 378/4885SMN1; SMN2 280/4885 |
| US-12070458-B2 | Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders | PYGB, GRN, BDNF | KMT2A 2003/4885LMNA 378/4885SMN1; SMN2 280/4885 |
| US-20240398792-A1 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING, RELIEVING, OR ALLEVIATING ALZHEIMER'S DISEASE | PSEN1, PSEN2, GRN | KMT2A 1488/4885LMNA 1167/4885SMN1; SMN2 1059/4885 |
| US-20090263334-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | KMT2A 2570/4885LMNA 3439/4885SMN1; SMN2 928/4885 |
| US-20230301994-A9 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | KMT2A 500/4885LMNA 3336/4885SMN1; SMN2 3863/4885 |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NLN, GAP43, BAD | KMT2A 2610/4885LMNA 419/4885SMN1; SMN2 42/4885 |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | QPCT, GRIA2, GGPS1 | KMT2A 500/4885LMNA 3336/4885SMN1; SMN2 3863/4885 |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | PARK7, ADCYAP1R1, LRRK2 | KMT2A 3004/4885LMNA 1415/4885SMN1; SMN2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.